Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis

Pei, Zerong; Chen, Shuting; Ding, Lei; Liu, Jingbo; Cui, Xinyi; Li, Fengyun; Qiu, Feng

doi:10.1016/j.jconrel.2022.10.023

Cited by 99 publications

(45 citation statements)

References 244 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…near‐infrasound) for selective eradication 236 . Nanomedicine is clearly the direction in which research and development will move in the coming years and decades 237 . Studies on materials with improved consistency, drug loading, and release capabilities would involve a further investigation.…”

Section: Recent Advancement In Nanomedicine and Drug Deliverymentioning

confidence: 99%

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Soni

Bhandari

Tripathi

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

In recent years, drug manufacturers and researchers have begun to consider the nanobiotechnology approach to improve the drug delivery system for tumour and cancer diseases. In this article, we review current strategies to improve tumour and cancer drug delivery, which mainly focuses on sustaining biocompatibility, biodistribution, and active targeting. The conventional therapy using cornerstone drugs such as fludarabine, cisplatin etoposide, and paclitaxel has its own challenges especially not being able to discriminate between tumour versus normal cells which eventually led to toxicity and side effects in the patients. In contrast to the conventional approach, nanoparticle-based drug delivery provides target-specific delivery and controlled release of the drug, which provides a better therapeutic window for treatment options by focusing on the eradication of diseased cells via active targeting and sparing normal cells via passive targeting. Additionally, treatment of tumours associated with the brain is hampered by the impermeability of the blood-brain barriers to the drugs, which eventually led to poor survival in the patients. Nanoparticle-based therapy offers superior delivery of drugs to the target by breaching the blood-brain barriers. Herein, we provide an overview of the properties of nanoparticles that are crucial for nanotechnology applications. We address the potential future applications

show abstract

Section: Recent Advancement In Nanomedicine and Drug Deliverymentioning

confidence: 99%

Nano‐biotechnology in tumour and cancerous disease: A perspective review

Soni

Bhandari

Tripathi

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The strength of the keyword bursts is an important indicator of the study’s hotspots, as well as emerging frontiers over time ( Pei et al, 2022 ). As illustrated in Figure 7C , the initial outbreak’s keywords were quantitative electroencephalography, cerebral blood flow, children, and universal synchronization.…”

Section: Resultsmentioning

confidence: 99%

“…The colors of nodes and lines represent different clusters. To evaluate the strength of the connections, the total link strength (TLS) index was used, representing the overall co-authorship and co-citation link strength among countries, institutions, or keywords ( Pei et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

Bibliometric analysis of electroencephalogram research in mild cognitive impairment from 2005 to 2022

Liu

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

BackgroundElectroencephalogram (EEG), one of the most commonly used non-invasive neurophysiological examination techniques, advanced rapidly between 2005 and 2022, particularly when it was used for the diagnosis and prognosis of mild cognitive impairment (MCI). This study used a bibliometric approach to synthesize the knowledge structure and cutting-edge hotspots of EEG application in the MCI.MethodsRelated publications in the Web of Science Core Collection (WosCC) were retrieved from inception to 30 September 2022. CiteSpace, VOSviewer, and HistCite software were employed to perform bibliographic and visualization analyses.ResultsBetween 2005 and 2022, 2,905 studies related to the application of EEG in MCI were investigated. The United States had the highest number of publications and was at the top of the list of international collaborations. In terms of total number of articles, IRCCS San Raffaele Pisana ranked first among institutions. The Clinical Neurophysiology published the greatest number of articles. The author with the highest citations was Babiloni C. In descending order of frequency, keywords with the highest frequency were “EEG,” “mild cognitive impairment,” and “Alzheimer’s disease”.ConclusionThe application of EEG in MCI was investigated using bibliographic analysis. The research emphasis has shifted from examining local brain lesions with EEG to neural network mechanisms. The paradigm of big data and intelligent analysis is becoming more relevant in EEG analytical methods. The use of EEG to link MCI to other related neurological disorders, and to evaluate new targets for diagnosis and treatment, has become a new research trend. The above-mentioned findings have implications in the future research on the application of EEG in MCI.

show abstract

“…Some of the aspects that have been so far neglected by the scientic community at the early design stage of drug nanocarriers are (i) the consequences of small chemical changes in the nanoparticle (NP) composition that affect drastically pharmacokinetic and -dynamic prole, (ii) the potential for production scale-up at affordable costs selecting, for example, inexpensive and/or biocompatible reagents, (iii) selection of preparation protocols that can assure reproducibility of different production batches as well as sustainability thanks to circular economy production processes. [16][17][18][19][20] Aware of this context we recently addressed the challenge of the implementation of multimodal therapy for CRPC focusing on polymers of cyclodextrins (CyDs) organizing in nanoparticles (NP) as valuable tool to opportunely assemble the various molecular players. CyDs are water soluble, biocompatible cyclic oligosaccharides, made of a-D-glucopyranose units joined by a(1-4) linkages (Scheme 1).…”

Section: Introductionmentioning

confidence: 99%

“…Some of the aspects that have been so far neglected by the scientific community at the early design stage of drug nanocarriers are (i) the consequences of small chemical changes in the nanoparticle (NP) composition that affect drastically pharmacokinetic and -dynamic profile, (ii) the potential for production scale-up at affordable costs selecting, for example, inexpensive and/or biocompatible reagents, (iii) selection of preparation protocols that can assure reproducibility of different production batches as well as sustainability thanks to circular economy production processes. 16–20…”

Section: Introductionmentioning

confidence: 99%